Management of fibromyalgia: What are the best treatment choices?

Drugs

Volumn 62, Issue 4, 2002, Pages 577-592

  Forseth, Karin Ø ^a   Gran, Jan T ^b  

^a Betanien Hospital   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; BOTULINUM TOXIN; BROMAZEPAM; CAFFEINE; CAPSAICIN; CARISOPRODOL; CITALOPRAM; CYCLOBENZAPRINE; DEXTROPROPOXYPHENE; FLUOXETINE; GROWTH HORMONE; IBUPROFEN; LIDOCAINE; METHADONE; MONOAMINE OXIDASE INHIBITOR; NAPROXEN; PARACETAMOL; PRAMIPEXOLE; PREDNISONE; S ADENOSYLMETHIONINE; SERTRALINE; TENOXICAM; TRAMADOL; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEEDBACK SYSTEM; FIBROMYALGIA; HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRANSCUTANEOUS NERVE STIMULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR THERAPY; BIOFEEDBACK (PSYCHOLOGY); CLINICAL TRIALS; FIBROMYALGIA; HUMANS; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 0036196878     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262040-00003     Document Type: Review

References (146)

1. The clinical syndrome of fibrositis
2. A controlled study of primary fibromyalgia syndrome: Clinical features and association with other functional syndromes
3. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee
4. The prevalence and characteristics of fibromyalgia in the general population
5. The epidemiology of the fibromyalgia syndrome (FMS) in German town
6. The prevalence of fibromyalgia in a south African community
7. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children
8. The prevalence of fibromyalgia among women aged 20-49 years in Arendal, Norway
9. Primary fibromyalgia: A clinical and laboratory study of 55 patients
10. Functional ability and work status in patients with fibromyalgia
11. The disability determination dilemma: Toward a multiaxial solution
12. The problem of longterm disability payments and litigation in primary fibromyalgia: The Canadian perspective
13. Longterm effects of fibromyalgia on everyday life: A study of 56 patients
14. Fibromyalgia and disability. Report of the Moss International Working Group on medico-legal aspects of chronic widespread pain complaints and fibromyalgia
15. The rise and possible fall of the Norwegian fibromyalgia epidemic: What does insurance statistics show
16. A population study of the incidence of fibromyalgia among women aged 26-55 yr
17. Epidemiologic research in fibromyalgia
18. Does primary fibromyalgia exist?
19. The course and topography of pain in fibromyalgia
20. A four-year follow-up study in fibromyalgia: Relationship to chronic fatigue syndrome
21. Primary fibromyalgia syndrome: An outcome study
22. Term follow-up of fibromyalgia patients: Clinical symptoms, muscular function, laboratory tests - An eight year comparison study
23. Fibromyalgia syndrome: Assessment of the severity of the condition 2 years after diagnosis
24. Fibromyalgia syndrome in children: An outcome study
25. One year outcome of preadolescents with fibromyalgia
26. A 5.5 years prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: Significance and natural history
27. Familial occurrence of primary fibromyalgia
28. Familial aggregation in the fibromyalgia syndrome
29. Genetic linkage analysis of multicase families with fibromyalgia syndrome
30. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia
31. Fibromyalgia and psychopathology: Is fibromyalgia a form of 'affective spectrum disorder'?
32. Confounding features of the fibromyalgia syndrome: A current perspective of differential diagnosis
33. Physical fitness and muscle metabolism in the fibromyalgia syndrome: An overview
34. Zur Myopathologie der generalisierten tendomyopathie
35. The muscle in fibromyalgia: A review of Swedish studies
36. Pathology of skeletal muscle in fibromyalgia: A histo-immuno-chemical and ultrastructural study
37. 'Fibrositis' as a disorder of pain modulation
38. Tender points: Evolution of concepts of the fibrositis/fibromyalgia syndrome
39. Fibrositis syndrome: A historical perspective
40. Towards a model of pathophysiology of fibromyalgia: Abberant central pain mechanisms with peripheral modulation
41. Pain a nociception in fibromyalgia: Clinical and neurobio-logical considerations on aetiology and pathogenesis
42. Advances in fibromyalgia: Possible role for central neurochemicals
43. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis
44. Pathogenesis of fibromyalgia: The neurohormonal hypothesis
45. Abnormal brain regional cerebral flow (rCBF) and cerebrspinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM)
46. Neurochemical pathogenesis of fibromyalgia syndrome
47. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: Implications for nitric oxide pathways
48. Sleep and musculoskeletal pain
49. Sleep and fibrosis syndrome
50. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients
51. Fibrositis (fibromyalgia) in rheumatoid arthritis
52. An association of fibromyalgia with primary Sjögren's Syndrome: A prospective study of 72 patients
53. Prevalence of fibromyalgia in systemic lupus erythematosus patients: Comment on the article by Middleton, et al.
54. The association between fibromyalgia and carpal tunnel syndrome in the population
55. Aerobics fitness in patients with fibrositis. A controlled study of respiratory gaz exchange and 133 xenon clearance from exercising muscle
56. Fitness characteristics and perceived exertion in women with fibromyalgia
57. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia
58. Effects of aerobic exercise versus stress management treatment in fibromyalgia: A 4.5 year prospective study
59. An exercise program in the treatment of fibromyalgia
60. Effects of aerobic exercise on pain perception, affect, and level of disability in individuals with fibromyalgia
61. Effects of a group activity program for fibromyalgia patients on physical fitness and well being
62. Physical fitness training in patients with fibromyalgia
63. Fibromyalgia outcome: The predictive values of symptom duration, physical activity, disability pension, and critical life events: A 4.5 year study
64. The role of physical therapy and physical modalities in pain management
65. Pain mechanism: A new theory
66. Management strategies for chronic pain
67. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS): Implications for clinical use of TENS
68. Is acupuncture effective in the treatment of fibromyalgia?
69. Electroacupuncture in fibromyalgia: Results of a controlled trial
70. EMG-biofeedback training in fibromyalgia syndrome
71. Biofeedback/relaxation training and exercise interventions for fibromyalgia: A prospective trial
72. Cognitive-behavioral therapy for primary fibromyalgia
73. Systematic review and meta-analyses of randomized controlled trials of cognitive behaviour therapy and behavioural therapy for chronic pain in adults, excluding headache
74. Self-management of fibromyalgia: The role of formal coping skills training and physical exercise training programs
75. Present state of medication therapy in fibromyalgia syndrome
76. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia
77. Short term effects of ibuprofen in primary fibromyalgia syndrome: A double-blind, placebo controlled trial
78. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: A double-blind, placebo-controlled study
79. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial
80. Treatment of fibromyalgia (Fibrositis syndrome): A parallel double-blind trial with carioprodol, paracetamol and caffeïne (Somadril comp) versus placebo
81. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia
82. Tramadol in the fibromyalgia syndrome: A controlled clinical trial versus placebo
83. Efficacy of tramadol in treatment of pain in fibromyalgia
84. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study
85. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia
86. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia
87. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia
88. Zopiclone in the treatment of sleep abnormalities in fibromyalgia
89. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients: A double-blind randomized trial
90. The effect of zolpidem in patients with FM: A dose ranging, double-blind, placebo controlled, modified crossover study
91. A double crossover trial of prednisone versus placebo in the treatment of fibrositis
92. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder
93. A double-blind placebo controlled trial of fluoxetine in fibromyalgia
94. A randomized controlled trial of citalopram inn the treatment of fibromyalgia
95. Fluoxetine combined with cyclobenzaprine in the treatment of fibromyalgia
96. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia
97. Citalopram in patients with fibromyalgia: A randomized, double-blind, placebo-controlled study
98. Comparison of amitriptyline and sertraline in the treatment of fibromyalgia
99. Evaluation of amitriptyline in primary fibrositis a double-blind, placebo-controlled study
100. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline
101. Clinical usefulness of amitriptyline in fibromyalgia: The results of 23 N-of-1 randomized controlled trials
102. Lidocaine injection versus dry needling to myofascial trigger point
103. Difference in pain relief after triggerpoint injections in myofascial pain patients with and without fibromyalgia
104. Triggerpoints and tenderpoints: One and the same? Does injection treatment help?
105. Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond
106. Treatment of chronic pain with antiepileptic drugs: A new era
107. A randomized, double-blind, placebo-controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia
108. Oral S-adenosylmethionine in primary fibromyalgia: Double-blind clinical evaluation
109. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia
110. Double-blind study of %-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome
111. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: A 90-day open study
112. Treatment of tension-type headache by local injection of botulinum toxin
113. Treatment of pain due to fibromyalgia with topical capsaicin: A pilot study
114. Effect of gammahydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia: Preliminary report
115. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of patients with fibromyalgia
116. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-lgG fusion molecule
117. Safety and efficacy of the dopamine agonist, pramipexole, on pain score for refractory fibromyalgia
118. Management of fibromyalgia: Rationale for the use of magnesium and malic acid
119. A pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine
120. Analgesic effect of ketamine in a patient with neuropathic pain
121. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients
122. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain
123. Supplemental dextromethorphan in the treatment of fibromyalgia: A double-blind, placebo-controlled study of efficacy and side-effects
124. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia
125. Efficacy and tolerability of tropisetron in primary fibromyalgia - A highly selective and competitive 5-HT3 receptor antagonist
126. Oral treatment of fibromyalgia with tropisetron given over 28 days: Influence on functional and vegetative symptoms, psychometric parameters and pain
127. Results of the intravenous administration of tropisetron in fibromyalgia patients
128. 5-hydroxytryptophan: A clinically-effective serotonin precursor
129. Botulinum toxin: New and expanded indications
130. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons
131. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia
132. The Use of NMDA-receptor Antagonists in the treatment of Chronic Pain
133. Intravenous infusoion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo
134. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
135. Continuous subcutaneous administration of the N-methyl-D-aspartatic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia
136. The effect of ketamine on phantom pain: A central neuropathic disorder maintained by peripheral input
137. NMDA rceptor blockade in chronic nuropathic pain: A comparison of ketamine and magnesium chloride
138. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-D-aspartate receptor blockade
139. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial
140. Effects of dextromethorphan in clinical doses on capsaicin-induced ongoing pain and mechanical hypersensitivity
141. Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design
142. Ineffectiveness of dextromethorphan in cancer pain
143. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists